December 2013

Latest update on Euroneut41 Project- HIV Vaccine

The Surrey Clinical Research Centre was recently at the centre of an international effort with European Commission funding to design and test a vaccine to prevent HIV/AIDS. The vaccine employed several highly innovative concepts including nasal delivery to produce strong genital tract immunity, liposomal formulation, and an uniquely designed active component to make virus-blocking antibodies. The SCRC conducted the first in human clinical trial of this product, drawing on its extensive expertise in translational medicine, mucosal immunology, and Phase 1 trial accreditation.

Trim content

 Accessibility | Contacting the University | Privacy | Cookies | Disclaimer | Freedom of Information

© 2002-2017 University of Surrey, Egerton Road, Guildford, Surrey, GU2 7XP, United Kingdom. +44 (0)1483 300800